These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 28166825)

  • 1. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.
    Wang Y; Wu DP; Liu QF; Qin YZ; Wang JB; Xu LP; Liu YR; Zhu HH; Chen J; Dai M; Huang XJ
    Blood; 2014 Sep; 124(12):1880-6. PubMed ID: 25082877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia].
    Gao HT; Zhang Y; Sun K; Guo JM; Chen YQ; Chen XL; Shi J; Niu XN; Wang F; Huo L
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):210-215. PubMed ID: 28395444
    [No Abstract]   [Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Zhao XS; Liu KY; Huang XJ
    J Mol Diagn; 2020 Feb; 22(2):188-195. PubMed ID: 31751675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse.
    Ommen HB; Ostergaard M; Yan M; Braendstrup K; Zhang DE; Hokland P
    Eur J Haematol; 2010 Feb; 84(2):128-32. PubMed ID: 19891700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
    Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
    Yang L; Chen WM; Dao FT; Zhang YH; Wang YZ; Chang Y; Liu YR; Jiang Q; Zhang XH; Liu KY; Huang XJ; Qin YZ
    Cancer Med; 2019 Sep; 8(12):5459-5467. PubMed ID: 31364309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
    Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
    Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
    Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
    Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
    Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
    Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tang Y; Zhou Z; Yan H; You Y
    Front Immunol; 2022; 13():810284. PubMed ID: 35185899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia.
    Tonks A; Pearn L; Musson M; Gilkes A; Mills KI; Burnett AK; Darley RL
    Leukemia; 2007 Dec; 21(12):2495-505. PubMed ID: 17898786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Leuk Res; 2013 Jul; 37(7):784-9. PubMed ID: 23528260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.
    Fan S; Shen MZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Zhao XS; Qin YZ; Chang YJ; Liu KY; Huang XJ; Mo XD
    Front Oncol; 2021; 11():773394. PubMed ID: 35070977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
    Rücker FG; Agrawal M; Corbacioglu A; Weber D; Kapp-Schwoerer S; Gaidzik VI; Jahn N; Schroeder T; Wattad M; Lübbert M; Koller E; Kindler T; Götze K; Ringhoffer M; Westermann J; Fiedler W; Horst HA; Greil R; Schroers R; Mayer K; Heinicke T; Krauter J; Schlenk RF; Thol F; Heuser M; Ganser A; Bullinger L; Paschka P; Döhner H; Döhner K
    Blood; 2019 Nov; 134(19):1608-1618. PubMed ID: 31554635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
    Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.
    Tobal K; Newton J; Macheta M; Chang J; Morgenstern G; Evans PA; Morgan G; Lucas GS; Liu Yin JA
    Blood; 2000 Feb; 95(3):815-9. PubMed ID: 10648391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.